HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ulrike Fiedler Selected Research

MP0250

10/2021First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
3/2018Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.
11/2017MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.
11/2017Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ulrike Fiedler Research Topics

Disease

11Neoplasms (Cancer)
11/2022 - 03/2006
5Inflammation (Inflammations)
04/2013 - 06/2004
1Breast Neoplasms (Breast Cancer)
11/2022
1Ascites
01/2020
1Ovarian Neoplasms (Ovarian Cancer)
01/2020
1Ovarian Epithelial Carcinoma
01/2020
1Multiple Myeloma
03/2018
1Macular Edema
04/2013
1Neoplasm Metastasis (Metastasis)
07/2012
1Renal Cell Carcinoma (Grawitz Tumor)
07/2012
1Hypertension (High Blood Pressure)
06/2012
1Hypoxia (Hypoxemia)
02/2011
1Uterine Cervical Neoplasms (Cancer of the Cervix)
07/2009
1Retinal Neovascularization
04/2005

Drug/Important Bio-Agent (IBA)

5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2021 - 02/2011
4MP0250IBA
10/2021 - 11/2017
4Proteins (Proteins, Gene)FDA Link
01/2020 - 07/2009
3Designed Ankyrin Repeat ProteinsIBA
11/2022 - 04/2013
3CytokinesIBA
03/2014 - 02/2009
3Angiopoietin-2IBA
06/2012 - 02/2006
2AngiopoietinsIBA
12/2006 - 06/2004
1ErbB Receptors (EGF Receptor)IBA
11/2022
1pertuzumabIBA
11/2022
1human ERBB2 proteinIBA
11/2022
1Trastuzumab (Herceptin)FDA Link
11/2022
1NivolumabIBA
01/2020
1pembrolizumabIBA
01/2020
1AntibodiesIBA
01/2020
1Bortezomib (Velcade)FDA Link
03/2018
1UbiquitinIBA
03/2014
1Carrier Proteins (Binding Protein)IBA
03/2014
1Fibronectins (Fibronectin)IBA
03/2014
1MP0112IBA
04/2013
1EverolimusFDA Link
07/2012
1LuciferasesIBA
07/2012
1Sorafenib (BAY 43-9006)FDA Link
07/2012
1Sunitinib (Sutent)FDA Link
07/2012
1Angiopoietin-1IBA
06/2012
1Messenger RNA (mRNA)IBA
02/2011
1Biomarkers (Surrogate Marker)IBA
04/2010
1OsteopontinIBA
04/2010
1Tumor Biomarkers (Tumor Markers)IBA
03/2006
1Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
03/2006
1AntigensIBA
03/2006
1SialomucinsIBA
03/2006
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2006
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
04/2005

Therapy/Procedure

2Therapeutics
03/2014 - 02/2009